The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Expected Market Size Of The Hepatorenal Syndrome Treatment Market From 2026 To 2030?
The hepatorenal syndrome treatment market has experienced robust expansion in recent years. It is anticipated to increase from $15.17 billion in 2025 to $16.1 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.1%. Historically, this growth has been driven by several factors, including limited awareness of HRS, the absence of standardized treatment protocols, the high mortality associated with liver failure, a dependency on conventional dialysis methods, and restricted access to advanced therapeutics.
The hepatorenal syndrome treatment market size is anticipated to undergo substantial growth over the next few years, with projections indicating it will expand to $21.12 billion by 2030, achieving a compound annual growth rate (CAGR) of 7.0%. This expansion during the forecast period is propelled by advancements in targeted therapies, the adoption of precision medicine methodologies, the broadening of healthcare infrastructure, the incorporation of AI and digital tools into patient monitoring, and a rise in investment toward novel drug development. Key trends influencing the market during this period include an increasing prevalence of chronic liver diseases, continuous improvements in renal replacement therapies, the development of personalized treatment approaches for HRS, the expansion of hospital and clinical infrastructure, and a growing emphasis on early diagnosis and monitoring.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10414&type=smp
Which Growth Drivers Are Contributing To The Progress Of The Hepatorenal Syndrome Treatment Market?
The increasing prevalence of fast-track and novel drug designations is anticipated to fuel the expansion of the hepatorenal syndrome treatment market in the future. These designations represent regulatory avenues designed to accelerate the development, assessment, and authorization of medications for severe illnesses with significant unmet needs, with the goal of delivering cutting-edge treatments to patients sooner. This increase in specialized drug designations is intended to speed up the creation of therapies for hepatorenal syndrome, fulfilling the critical demand for effective treatments, potentially enhancing patient results, and addressing the condition’s unresolved medical requirements. As an illustration, the New Drug Therapy Approvals 2023 report, issued by the US-based Center for Drug Evaluation and Research (CDER), a branch of the U.S. Food and Drug Administration (FDA), in January 2024, revealed that 55 novel drugs received approval from CDER in 2023, of which 20 (36%) were classified as first-in-class, a rise from 37 novel drug approvals in 2022. Consequently, the uptick in fast-track and novel drug designations is a key factor propelling the expansion of the hepatorenal syndrome treatment market.
Which Segments Are Included In The Analysis Of The Hepatorenal Syndrome Treatment Market?
The hepatorenal syndrome treatment market covered in this report is segmented –
1) By Type: Type 1 Hepatorenal Syndrome, Type 2 Hepatorenal Syndrome
2) By Treatment: Therapeutics, Surgical Treatment
3) By End-User: Hospitals And Clinics, Ambulatory Surgical Centers, Academic And Research Institutes, Other End-Users
Subsegments:
1) By Type 1 Hepatorenal Syndrome: Intravenous Albumin, Vasopressors, Dialysis, Liver Transplantation
2) By Type 2 Hepatorenal Syndrome: Albumin Infusion, Midodrine, Octreotide, Liver Transplantation
Which Trends Are Impacting The Growth Of The Hepatorenal Syndrome Treatment Market?
Leading companies operating in the hepatorenal syndrome treatment market are prioritizing the development of innovative advancements, such as vasoconstrictive renal-support therapies, to enhance kidney function and clinical outcomes for patients experiencing rapid deterioration linked to advanced liver disease. A vasoconstrictive renal-support therapy represents a pharmacological intervention crafted to improve renal perfusion and facilitate kidney recovery by selectively constricting splanchnic blood vessels and stabilizing circulatory function. As an illustration, in June 2024, Mallinckrodt plc, an Ireland-based specialty pharmaceutical firm, unveiled new clinical data regarding TERLIVAZ, a terlipressin injection approved for hepatorenal syndrome involving a rapid reduction in kidney function. The presented findings demonstrated advantageous outcomes across several patient cohorts, including better reversal rates of kidney dysfunction and a diminished requirement for renal replacement therapy. This data further emphasized the therapy’s importance in addressing a critical, life-threatening complication of advanced liver disease and its capacity to guide earlier diagnosis and more effective clinical management approaches.
Which Key Industry Participants Are Active In The Hepatorenal Syndrome Treatment Market?
Major companies operating in the hepatorenal syndrome treatment market are BioVie Inc., Cumberland Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Orphan Therapeutics LLC, Baxter International Inc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, Boehringer Ingelheim GmbH, Bayer AG, Gilead Sciences Inc., Pfizer Inc., AstraZeneca PLC, AbbVie Inc., Amgen Inc., F Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd, Astellas Pharma Inc., Kyowa Kirin Co Ltd
Read the full hepatorenal syndrome treatment market report here:
What Are The Leading Geographic Regions In The Hepatorenal Syndrome Treatment Market?
North America was the largest region in the hepatorenal syndrome treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global hepatorenal syndrome treatment market during the forecast period. The regions covered in the hepatorenal syndrome treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Hepatorenal Syndrome Treatment Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=10414&type=smp
Browse Through More Reports Similar to the Global Hepatorenal Syndrome Treatment Market 2026, By The Business Research Company
Hepatorenal Syndrome Treatment Market Report 2026
Alcoholic Hepatitis Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/alcoholic-hepatitis-treatment-global-market-report
Liver Diseases Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model